SCHEMBL1898080

SCHEMBL1898080

CN(C)c1ccc(/C=C/c2cc[n+](C)cc2)cc1

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.96
KMT2A Q03164 7/20 0.96
MAPT P10636 5/20 0.96
SMN1; SMN2 Q16637 4/20 0.96
ALDH1A1 P00352 3/20 0.96
HTT P42858 3/20 0.96
GFER P55789 2/20 0.96
LMNA P02545 2/20 0.96
THRB P10828 2/20 0.96
NPSR1 Q6W5P4 2/20 0.96
ALPG P10696 1/20 0.96
CASP1 P29466 2/20 0.69
HBB P68871 2/20 0.69
GAA P10253 2/20 0.69
BRCA1 P38398 1/20 0.69
CASP7 P55210 1/20 0.69
RELA Q04206 1/20 0.61
APP P05067 4/20 0.59
RAB9A P51151 6/20 0.57
NPC1 O15118 5/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1898081 1.00 MEN1 (0.96) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL28626066 0.98 MEN1 (0.92) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
Iodide SCHEMBL531167 0.98 MEN1 (1.00) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL28626064 0.98 MEN1 (0.92) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
Iodide SCHEMBL531166 0.98 MEN1 (1.00) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
Iodide SCHEMBL31193459 0.90 MEN1 (0.86) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
Iodide SCHEMBL31553417 0.90 MEN1 (0.86) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
Perchlorate SCHEMBL29959624 0.86 MAPT (0.72) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL7034006 0.85 MEN1 (0.71) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL15624211 0.85 ALDH1A1 (0.71) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12596125-B2 Nano-rheological biomarkers for early and improved follow-up of pathologies associated to RBC deformability alteration ALCEDIAG (FR) 2026-04-07 US claimed
US-20220299533-A1 NANO-RHEOLOGICAL BIOMARKERS FOR EARLY AND IMPROVED FOLLOW-UP OF PATHOLOGIES ASSOCIATED TO RBC DEFORMABILITY ALTERATION UNIVERSITÉ PARIS CITÉ (FR) 2022-09-22 US claimed
EP-3983802-A1 NANO-RHEOLOGICAL BIOMARKERS FOR EARLY AND IMPROVED FOLLOW-UP OF PATHOLOGIES ASSOCIATED TO RBC DEFORMABILITY ALTERATION ALCEDIAG (FR) 2022-04-20 EP claimed
EP-2516995-B1 SERS-BASED ANALYTE DETECTION AGENCY SCIENCE TECH & RES (SG) 2016-10-26 EP claimed
WO-2010144438-A1 PHOTOVOLTAIC DEVICE WITH FREQUENCY CONVERSION REGION WAKE FOREST UNIVERSITY (US) 2010-12-16 WO claimed
EP-1200051-B1 AGENT FOR DYING KERATIN FIBERS HENKEL KGAA (DE) 2006-02-01 EP claimed
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-03-03 US claimed
EP-1121567-B1 LUMINESCENT BRITTLE COATING IN STRAIN ANALYSIS UNIV FLORIDA (US) 2004-09-15 EP claimed
EP-1303311-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF Neurochem, Inc. (CA) 2003-04-23 EP claimed
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (GI) 2002-08-22 US claimed
WO-2002007781-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF NEUROCHEM INC. (CA) 2002-01-31 WO claimed
US-12596125-B2 Nano-rheological biomarkers for early and improved follow-up of pathologies associated to RBC deformability alteration ALCEDIAG (FR) 2026-04-07 US disclosed
WO-2024058527-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS COMPRISING ESOMEPRAZOLE OR DEXLANSOPRAZOLE AS ACTIVE INGREDIENT 고려대학교 산학협력단 2024-03-21 WO disclosed
US-20230240954-A1 USE OF ANTHRAQUINONE DYES AND OF FLUORESCENT DYES FOR DYEING KERATIN FIBRES, DYEING PROCESS AND COMPOSITION L'OREAL (FR) 2023-08-03 US disclosed
US-20220299533-A1 NANO-RHEOLOGICAL BIOMARKERS FOR EARLY AND IMPROVED FOLLOW-UP OF PATHOLOGIES ASSOCIATED TO RBC DEFORMABILITY ALTERATION UNIVERSITÉ PARIS CITÉ (FR) 2022-09-22 US disclosed
EP-1303311-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF Neurochem, Inc. (CA) 2003-04-23 EP disclosed
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof NEUROCHEM (INTERNATIONAL) LIMITED (GI) 2002-08-22 US disclosed
US-6402037-B1 Two-photon upconverting dyes and applications THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2002-06-11 US disclosed
WO-2002007781-A2 AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF NEUROCHEM INC. (CA) 2002-01-31 WO disclosed
US-5912257-A COMPRISING A MATRIX AND STYRYL DYES AND CPOPOSITIONS SHOWING SUPERIOR TWO PHOTON ABSORPTION CROSS-SECTIONS; LASER COMPRISING SOUCE CAPABLE OF PRODUCING INFRARED RADIATION; MULTIPHASE MULTISTRUCTURAL COMPOSITES THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1999-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12596125-B2 Nano-rheological biomarkers for early and improved follow-up of pathologies associated to RBC deformability alteration SPTBN1, MB, HBZ MEN1 430/4885KMT2A 2529/4885MAPT 2110/4885
US-20050048000-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 MEN1 605/4885KMT2A 3512/4885MAPT 10/4885
US-20230240954-A1 USE OF ANTHRAQUINONE DYES AND OF FLUORESCENT DYES FOR DYEING KERATIN FIBRES, DYEING PROCESS AND COMPOSITION KRT18, CUTA, KLK5 MEN1 2794/4885KMT2A 2181/4885MAPT 1599/4885
US-20020115717-A1 Amyloid targeting imaging agents and uses thereof APP, APBA1, BACE1 MEN1 605/4885KMT2A 3512/4885MAPT 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.